Savara announced today that encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-13, 2025, in Tokyo, Japan. For more information: https://bit.ly/42hL8lK
Savara Inc.
Pharmaceutical Manufacturing
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.
About us
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com.
- Website
-
http://www.savarapharma.com
External link for Savara Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- United States
- Type
- Public Company
- Founded
- 2007
- Specialties
- biotech, biopharma, pulmonary, dry-powder, dpi, therapeutics, lung, respiratory, aerosol, inhaler, drug delivery, and rare disease
Locations
-
Primary
Get directions
United States
United States, US
Employees at Savara Inc.
-
Larry Corrigan
Commercial Analytics Leader | Rare Disease | Data Strategy & Enablement
-
Paul Gratt
Start-up Biotech |Sales Executive | Sales Leadership | Team Building | Sales Infrastructure and Support Build-out | Product Launches
-
Ricky Sun
Partner, Bain Capital Life Sciences
-
Cristina D'Antonio
Healthcare GMP- Industria Farma, Vet, Cosméticos y Domisanitarios. SQA Services Associate. Auditor lider ISO 9001:2015
Updates
-
During Autoimmune Awareness Month, it is important to highlight the patients who are at the heart of what we do. Meet Leah, a woman living with autoimmune pulmonary alveolar proteinosis (aPAP), a rare respiratory disease. Find out what it’s like to live with aPAP: https://bit.ly/4iy6DFH #AutoimmuneAwarenessMonth
-
Recent Announcement: Today, Savara reported fourth quarter and year end 2024 financial results and provided a business update. For more information: https://lnkd.in/gpJFh8Z6
-
Recent Announcement: Savara enters into a non-dilutive debt financing for up to $200M with Hercules Capital. For more information: https://bit.ly/4iIoJoA
-
Recent Announcement: Savara completes submission of the BLA to the FDA for MOLBREEVI as a treatment for autoimmune PAP. For More Information: https://bit.ly/4iI5TOH
-
March is Autoimmune Awareness Month. Did you know? Over 50 million Americans live with autoimmune diseases, yet many are still undiagnosed. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy tissues, proteins, or organs. Let’s raise awareness together! For more information on autoimmune pulmonary alveolar proteinosis (aPAP), visit: https://bit.ly/4iRoh7t #AutoimmuneAwarenessMonth @Autoimmune Association
-
Savara announces new data from the Phase 3 IMPALA-2 trial of molgramostim inhalation solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (aPAP) will be presented at the American Thoracic Society International Conference in May. For more information: https://bit.ly/4bXFwS5
-
We are proud to announce the launch of the aPAP ClearPath™ Dried Blood Spot (DBS) Test. With only a finger-prick blood sample, the DBS test helps obtain a diagnosis of autoimmune pulmonary alveolar proteinosis (aPAP), a rare autoimmune lung disease caused by antibodies targeting GM-CSF. This is a key pathway to delivering innovation for aPAP patients and their physicians. For more information: https://bit.ly/4hdECSC
-
On Tuesday, March 11th, members of the Savara management team will attend the Leerink Global Healthcare Conference in Miami and participate in a fireside chat. For more information: https://bit.ly/3DjHi33
-
Savara is proud to sponsor the upcoming webinar “How Asthma Can Mask Rare Lung Diseases,” hosted by the American Lung Association. Please join us for this free event! For more information and to register for the event: https://bit.ly/4kaGaPO